Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
Location: United States, California, San Carlos
Employees: 11-50
Total raised: $228M
Founded date: 2014
Investors 5
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | MBC BioLab... | mbcbiolabs... |
| - | For Good V... | forgoodven... |
| 28.06.2021 | Abingworth... | abingworth... |
| - | Chiesi Ven... | chiesivent... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 21.04.2025 | Series C | $115M | - |
| 25.06.2021 | Series B | $68M | - |
| 07.08.2019 | Series B | $33M | - |
| 26.11.2016 | Series A | $12M | Chiesi Ven... |
Mentions in press and media 17
| Date | Title | Description |
| 21.04.2025 | Glycomine: $115 Million (Series C) Raised To Advance GLM101 Drug Candidate | Glycomine – a biotechnology company focused on developing transformative new therapies for orphan diseases – announced a $115 million Series C financing to advance its lead candidate GLM101, into a Phase 2b clinical trial. This funding was ... |
| 16.04.2025 | Glycomine Banks $115 Million Series C | SAN CARLOS, CA, Glycomine, a biotechnology company focused on developing transformative new therapies for orphan diseases, announced a $115 million Series C. >> Click here for more funding data on Glycomine >> To export Glycomi... |
| 16.04.2025 | When and Why Should You Hire a Securities Lawyer? | Securities law plays a crucial role in regulating financial markets and protecting investors from fraudulent activities. In New Orleans, the significance of this field is highlighted by recent legal actions, such as the Securities and Excha... |
| 16.04.2025 | Glycomine grabs $115M series C to fund phase 2 journey for rare genetic disorder drug | Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder. The asset in question, dubbed GLM101, is a mannose-1-phosphate replacement therapy. G... |
| 16.04.2025 | Glycomine Raises $115M in Series C Financing | Glycomine, a San Carlos, CA-based biotechnology company focused on developing new therapies for orphan diseases, raised $115M in Series C funding. The round was led by CTI Life Sciences Fund, abrdn Inc., and Advent Life Sciences, with parti... |
| 25.06.2021 | Glycomine Raises $68M in Series B Funding | Glycomine, Inc., a San Carlos, Calif.-based biotechnology company focused on developing new therapies for orphan diseases, closed a $68m Series B financing. The round, which included $35m of new funds in addition to the $33m announced in Au... |
| 23.06.2021 | Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease | - |
| 23.06.2021 | Glycomine Closes $68M Series B Funding | SAN CARLOS, CA, Glycomine has closed a $68 million Series B financing led by Abingworth and Sanofi Ventures. >> Click here for more funding data on Glycomine >> To export Glycomine funding data to PDF and Excel, click here ... |
| 23.06.2021 | Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease | Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, today announced that it has closed a $68 million Series B financing. The proceeds of the financing will be used to advance Glycomine’s lead dr... |
| 07.08.2019 | Glycomine Closes $33 Million Series B | Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to adv... |
Show more